Valeant Pharmaceuticals International, Inc. (VRX) held by 66 SEC 13F Filers

Saba Capital Management Lp increased Valeant Pharmaceuticals Intl (VRX) stake by 122.78% reported in 2016Q4 SEC filing. The lowest sales estimate is $2.06 billion and the highest is $2.24 billion. (NYSE:VRX) reached 59.45% versus a 1-year low price of $8.31. The business is expected to report its next earnings results before the market opens on Tuesday, May 9th. CIBC World Markets Inc. now owns 3,819,702 shares of the specialty pharmaceutical company's stock worth $93,774,000 after buying an additional 122,820 shares during the period. Public Sector Pension Investment Board increased its position in Valeant Pharmaceuticals Intl by 3.1% in the fourth quarter. The specialty pharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.87 by $1.93.

The company's net profit margin stands at 4.60% whereas its return on equity (ROE) is 4.50%. Analyst's mean target price for CYTR is $4.00 while analysts mean recommendation is 2.00. The firm's quarterly revenue was down 11.1% on a year-over-year basis. The business's quarterly revenue was down 11.1% compared to the same quarter past year. BTIG Research reaffirmed a "neutral" rating on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, May 10th. Royal Bank of Canada reiterated a "sector perform" rating and set a $22.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, February 28th.

While taking a look at financials, we can look at a number of key indicators about Valeant Pharmaceuticals International, Inc. On Friday, August 14 the stock rating was maintained by Jefferies with "Buy". The stock is presently down its SMA-50 of $7.09. If you are viewing this report on another publication, it was stolen and republished in violation of United States & global copyright and trademark laws. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of USA and global copyright & trademark laws. Finally, Morgan Stanley boosted its position in shares of Valeant Pharmaceuticals Intl by 241.6% in the third quarter. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has risen 6.00% since April 18, 2017 and is uptrending. Valeant Pharmaceuticals Intl now has $4.27B valuation. Therefore stocks with higher earnings growth should offer the highest capital gains. Herendeen Paul had bought 24,000 shares worth $257,280. If the average volume is low then the liquidity is low which means it is hard to buy or sell the stock as there are fewer buyers or sellers of the stock. Deutsche Bank AG dropped their price objective on shares of Valeant Pharmaceuticals Intl from $20.00 to $19.00 and set a "hold" rating for the company in a research note on Tuesday, March 7th. Fosun International Ltd now owns 303,708 shares of the specialty pharmaceutical company's stock worth $7,456,000 after buying an additional 36,738 shares during the last quarter. 11, 2017. These shares are worth $278,000 and were traded at $13.9 each. Following the acquisition, the director now owns 70,572 shares in the company, valued at approximately $980,950.80. The disclosure for this purchase can be found here. Maybe the focus is on finding a stock that has recently taken a turn for the worse for no real apparent reason. (NYSE:VRX) by some 42,997,872 shares, 148 decreased positions by 65,834,268 and 66 held positions by 69,652,180. AlphaOne also assigned media stories about the specialty pharmaceutical company an impact score of 43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. Warren Averett Asset Management LLC raised its stake in Valeant Pharmaceuticals Intl by 14.0% in the first quarter. Over the last three months, the shares of the company have changed -40.57% and performed -16.98% over the last six months.

What Technical say about Valeant Pharmaceuticals International, Inc. Private Management Group Inc. now owns 356,168 shares of the specialty pharmaceutical company's stock worth $8,744,000 after buying an additional 8,116 shares during the last quarter. The stock has "Buy" rating by Rodman & Renshaw on Tuesday, February 16.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company.

Latest News